ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Malignant Ovarian Epithelial Tumor · Platinum-Resistant Fallopian Tube Carcinoma · Platinum-Resistant Ovarian Carcinoma · Platinum-Resistant Primary Peritoneal Carcinoma · Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma · Refractory Fallopian Tube Carcinoma · Refractory Ovarian Carcinoma · Refractory Primary Peritoneal Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

    Contact: Study coordinator (Clinical Trials Office) · (800) 527-6266
    Robert Morris, M.D. (Sub-investigator)
    Contact: Principal Investigator (Ira Winer, M.D.)
    Radhika Gogoi, M.D. (Sub-investigator)
  • Karmanos Cancer Institute at McLaren Flint, Flint, Michigan, United States

    Contact: Study coordinator (John J Wallbillich, M.D.) · jwallbil@med.wayne.edu
Study leads
  • Ira Winer, M.D.

    Principal Investigator

    Barbara Ann Karmanos Institute